ILUVIEN eye implant for kids with recurrent eye inflammation
Part of Eyes & vision clinical trials.
This trial tests an eye implant (ILUVIEN) in children and teens ages 6 to 17 who have a type of eye inflammation called uveitis that keeps coming back. The implant releases medicine slowly over time to control inflammation and may help reduce the need for other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 17 years old.
- You have eye inflammation (uveitis) in the back part of one or both eyes that comes back at least once a year.
- Current treatments for this eye inflammation haven't worked well or have caused bad side effects.
- You have taken steroid pills or other body-wide treatments for at least 3 months in the past year.
- You have not had eye surgery in the study eye in the last 90 days.
- You do not have glaucoma or high eye pressure that is not well controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how often inflammatory flare-ups happen in patients with a type of eye inflammation called posterior uveitis. It focuses on people who have been treated with a fluocinolone acetonide implant, a tiny device placed in the eye that releases medicine over time, and aims to understand how well it controls inflammation.
This trial tests whether a small steroid implant placed inside the eye (YUTIQ 0.18 mg) can control chronic non-infectious uveitis. It may help reduce active inflammation and prevent flare-ups, as long as you’ve had recent signs of active disease and can follow the medication and eye-visit rules.
This study follows adults with non-infectious uveitis (intermediate, posterior, or pan-uveitis) to better understand inflammation activity and treatment needs. It also follows adults having planned eye surgery (like cataract or vitreoretinal surgery) to compare groups.
This trial tests a new drug called FXS5626 to treat non-infectious uveitis—inflammation inside the eye that doesn't come from infection. The study looks at whether this drug can reduce eye inflammation and improve vision in people whose condition isn't controlled with steroid eye drops and oral steroids alone.
This trial tests a new eye drop (tacrolimus) to treat non-infectious anterior uveitis, an inflammation in the front part of the eye. It may help reduce the need for steroid eye drops.
This study tests whether receiving two YUTIQ injections works better than a sham (fake) treatment for long-lasting inflammation inside the back part of the eye. It is meant to reduce ongoing “posterior segment” inflammation and improve comfort and eye health when prior steroid treatments have helped but the inflammation keeps coming back.
Hear when a new Non-infectious Uveitis Affecting the Posterior Segment of the Eye trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.